Sangamo Therapeutics, Inc.

Good afternoon and welcome to the Sangamo Therapeutics fourth quarter and full year 2024 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today. Please go ahead.

Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo Executive Leadership Team, including Sandy McRae, Chief Executive Officer, Natalie Dubar-Stringfellow, Chief Development Officer, and Pratisha Durrababu, Chief Financial Officer. Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, Statements related to Sangamo's cash runway, plans to obtain additional capital and ability to continue operating as a going concern. The therapeutic and commercial potential and value of Sangamo's product candidates and technologies. Sangamo's ability to earn and receive payments from its collaboration and license agreements. Sangamo's expectations regarding new collaborations and license agreements. the anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and releases, regulatory submissions, regulatory approvals, upcoming catalysts and milestones, and other statements that are not historical fact. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filing for the SEC, specifically in our annual report on Form 10-K. The fiscal year ended December 31, 2024. and subsequent filings and reports that Sangoma makes from time to time with the SEC. The forward-looking statements stated today are made as of today, and we undertake no duty to update such information except as required by law. Please note that all forward-looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding. Now, I'll turn the call over to our CEO, Sandy McRae.

Thank you, Louise, and good afternoon to everyone joining the call today. Sango's pipeline has made a great deal of progress since the start of 2024. We have advanced our prioritised neurology therapies towards the clinic, securing our first-ever neurology IND in idiopathic small fibre neuropathy for chronic neuropathic pain and demonstrating non-clinical proof of concept for a product candidate in prion disease. We showed that we are a collaborator of choice for neurotropic capsids with the announcement of two blue-chip pharma agreements for our industry-leading delivery capsid, STAC-BBB, the first with Genentech for tau and a second neurology target, and the second with Astellas for up to five neurology disease targets. We have a clear regulatory pathway to accelerated approval in Fabry disease, which could reduce the time to potential approval by approximately three years. And our Fabry-June therapy study continues to generate best in class data with a pivotal data readout expected in mid 2025. From a financial standpoint, since 2023, we have reduced our non-GAAP operating expenses by nearly half year over year. And in 2024, we raised over 100 million in funding through non-dilutive license fees and milestone payments, as well as equity financing. And these are significant achievements for a company of our size. Judged by all other metrics, this would have been a very successful year. However, we know until we partner Fabry and appropriately capitalise the company for success, our work is not done. I want to re-emphasise that our number one priority continues to be addressing our financial needs. Sangamo must be well capitalised to fulfil our potential. We continue to engage in Fabry business development negotiations and securing a commercial partner is our key focus. Interest in this program has been strong. This is proving to be a time consuming process as discussions of this nature are complex and facilitating the extensive due diligence required by potential partners takes time. We remain committed to securing an anticipated partnership in the second quarter of 2025 that is best suited to bringing ST920 to Fabry patients upon potential approval and that provides capital for Sango to execute on its other programmes. We will share information as soon as we are able. Furthermore, we are actively engaged in advanced contract negotiations with a potential collaborator for third stack BBB license agreement and are hopeful of having more news to share near the end of this quarter. I would now like to hand it over to Natalie, our Head of Development, who will walk us through detailed pipeline developments. Natalie.